Dupilumab significantly reduced airway inflammation in patients with uncontrolled, moderate-to-severe type 2 asthma. Read now.

Researchers found increased odds for clinical remission on dupilumab with high blood eosinophil and fractional exhaled nitric ...

Discover a proof-of-concept study that was conducted to explore whether dupilumab could induce desensitisation to peanut.

Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant reductions were also seen in ...

The most common adverse events in the dupilumab group (occurring in at least three patients) included peripheral edema, arthralgia, back pain, blurred vision, hypertension, asthma, conjunctivitis ...

Positive results from ADEPT phase 2/3 study of Dupixent in adults with moderate-to-severe bullous pemphigoid presented at AAD: Paris Tuesday, March 11, 2025, 14:00 Hrs [IST] Posit ...

Positive results from the pivotal ADEPT phase 2/3 study evaluating the investigational use of Dupixent (dupilumab) in adults with moderate-to-severe bullous pemphigoid (BP) were shared in a ...

Asthma is a chronic respiratory disease affecting ... Biologic drugs like monoclonal antibodies (e.g., dupilumab, mepolizumab, and omalizumab) have been designed to block key cytokines such ...

Cyr, PhD, MBA, of Regeneron Pharmaceuticals, reported at the American Academy of Allergy, Asthma & Immunology annual ... "It's nothing that the dupilumab is doing, it's that the dupilumab's ...

1 Dupilumab is being jointly developed by Regeneron ... or inhaled corticosteroid medicines; have asthma and use an asthma medicine; or have atopic dermatitis, chronic rhinosinusitis with nasal ...